Peripheral CD56(+)CD16(+) NK Cell Populations in the Early Follicular Phase Are Associated With Successful Clinical Outcomes of Intravenous Immunoglobulin Treatment in Women With Repeated Implantation Failure

doi:10.3389/fendo.2019.00937

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24329

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24329

Title:	Peripheral CD56(+)CD16(+) NK Cell Populations in the Early Follicular Phase Are Associated With Successful Clinical Outcomes of Intravenous Immunoglobulin Treatment in Women With Repeated Implantation Failure
Authors:	Ho, YK;Chen, HH;Huang, CC;Lee, CI;Lin, PY;Lee, MS;Lee, TH
Keywords:	natural killer cells;intravenous immunoglobulin;repeated implantation failure;infertility;lymphocytes
Date:	2020
Issue Date:	2022-08-09T08:00:31Z (UTC)
Publisher:	FRONTIERS MEDIA SA
ISSN:	1664-2392
Abstract:	The percentage of peripheral CD56(+)CD16(+) NK cells in the early follicular phase on days 2-3 of the menstrual cycle in repeated implantation failure (RIF) patients was used to evaluate the impact of intravenous immunoglobulin (IVIG) on ART cycles. A total 283 patients with RIF consisting of at least 3 ART failures and at least 2 high quality embryo transfers were recruited. A logistic regression analysis for the peripheral immunological profile was completed to predict implantation success and compare the implantation and pregnancy rates between groups with <= 10.6 and >10.6% of CD56(+)CD16(+) NK cells in the early follicular phase. The logistic regression and receiving operating curve analyses showed that patients with <= 10.6% of peripheral CD56(+)CD16(+) NK cells in the early follicular phase showed a lower pregnancy rate within the RIF group without IVIG. Patients with peripheral CD56(+)CD16(+) NK cells <= 10.6% and without IVIG treatment showed significantly lower implantation and pregnancy rates (12.3 and 30.3%, respectively) when compared with the CD56(+)CD16(+) NK cells >10.6% group (24.9 and 48.0%, respectively, p < 0.05). Furthermore, the patients with CD56(+)CD16(+) NK cells <= 10.6% given IVIG starting before ET had significantly higher implantation, pregnancy, and live birth rates (27.5, 57.4, and 45.6%, respectively) when compared with the non-IVIG group (12.3, 30.3, and 22.7%, respectively, p < 0.05). Our results showed that a low percentage of peripheral CD56(+)CD16(+) NK cells (<= 10.6%) in the early follicular phase is a potential indicator of reduced pregnancy and implantation success rates in RIF patients, and IVIG treatment will likely benefit this patient subgroup.
URI:	http://dx.doi.org/10.3389/fendo.2019.00937 https://www.webofscience.com/wos/woscc/full-record/WOS:000511318200001 https://ir.csmu.edu.tw:8080/handle/310902500/24329
Relation:	FRONTIERS IN ENDOCRINOLOGY ,2020 ,v10
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	202	View/Open

Loading...